Genedrive Plc - Company Profile
Powered by
All the data and insights you need on Genedrive Plc in one report.
- Save hours of research time and resources with
our up-to-date Genedrive Plc Strategy Report
- Understand Genedrive Plc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Related keylists
Genedrive Plc (Genedrive) formerly Epistem Holdings Plc specializes in the development of point-of-care molecular diagnostic platforms. The company's major activities include the creation of innovative tests for various clinical indications such as genotyping, pathogen detection, and infectious disease detection. The company's major products include the Genedrive MT-RNR1 ID kit, used for detecting antibiotic-induced hearing loss in neonates, and the Genedrive CYP2C19 ID kit, a rapid point-of-care test for CYP2C19 genotyping. The company's products are primarily used in healthcare settings, particularly in emergency medicine, for patient stratification and disease detection. The company provides its products in North America, Asia Pacific, Europe, Middle East and Africa (EMEA) region through its distribution partners. Genedrive is headquartered in Manchester, the UK.
Genedrive Plc premium industry data and analytics
Products and Services
Products | Brands |
---|---|
Genedrive HCV ID Kit | Genedrive |
Genedrive 96 SARS-CoV-2 Kit | |
Genedrive MT-RNR1 ID Kit | |
XYZ | |
XYZ | |
XYZ |
Competitor Comparison
Key Parameters | Genedrive Plc | GSK plc | GenMark Diagnostics Inc | Immunodiagnostic Systems Holdings Ltd | Tiziana Life Sciences Plc |
---|---|---|---|---|---|
Headquarters | United Kingdom | United Kingdom | United States of America | United Kingdom | United Kingdom |
City | Manchester | Brentford | Carlsbad | Tyne and Wear | Hamilton |
State/Province | England | England | California | Tyne and Wear | South Lanarkshire |
No. of Employees | 43 | 69,400 | - | 16 | 9 |
Entity Type | Public | Public | Private | Private | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
Name | Position | Board | Since | Age |
---|---|---|---|---|
James Bernard Cheek | Director; Chief Executive Officer | Executive Board | 2023 | 57 |
Russell Shaw | Chief Financial Officer; Director | Executive Board | 2022 | 45 |
Gino Miele | Chief Scientific Officer | Senior Management | 2023 | 54 |
Ian Gilham, Ph.D. | Chairman | Non Executive Board | 2015 | 64 |
Chris Yates | Director | Non Executive Board | 2018 | 50 |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward